This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-27 and is reviewed periodically as new material appears.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
The "Lemon Tek" method of consumption results in a more rapid onset and can offer easier digestion or reduced "come-up pressure" associated with raw consumption. Upon ingestion, effects usually begin after approximately 20–60 minutes (depending on the method of ingestion and stomach contents) and may last from four to ten hours, depending on dosage, potency of cultivar, and individual biochemistry. Visual distortions often occur, including walls that seem to breathe, a vivid enhancement of colors, and the animation of organic shapes. The effects of high doses can be overwhelming depending on the particular phenotype of cubensis, grow method, and the individual. It is recommended not to eat wild mushrooms without properly identifying them as they may be poisonous. In particular, similar species include mushrooms of the genus Galerina and Pholiotina rugosa—all potentially deadly—and Chlorophyllum molybdites. All of these grow in pastures, a similar habitat to that preferred by P. cubensis.
S0 + hν → S1 S1 + S1 → S0 + Sn S1 + Sn → M+ + M− where S0 is the ground electronic state, S1 the first electronic excited state, and Sn is a higher electronic excited state. The product ions can be proton transfer or electron transfer ion pairs, indicated by M+ and M− above. Secondary processes involve ion-molecule reactions to form analyte ions.
=== Sources === Abdelal, Rawi; Bros, Aurélie (2020). "The End of Transatlanticism?: How Sanctions Are Dividing the West". Horizons: Journal of International Relations and Sustainable Development. 16 (16). Center for International Relations and Sustainable Development: 114–135. JSTOR 48573754. Davis, Stuart; Ness, Immanuel, eds. (2023). Sanctions as War: Anti-Imperialist Perspectives on American Geo-Economic Strategy. Haymarket Books. ISBN 978-1-64259-812-4. OCLC 1345216431. Beal, Tim. "2: Sanctions as Instrument of Coercion: Characteristics, Limitations, and Consequences". In Davis (ed) 2023, pp. 27–50. Bridenthal, Renate. "19: Blowback to US Sanctions Policy". In Davis (ed) 2023, pp. 323–332. Davis, Stuart. "4: Economic Sanctions, Communications Infrastructures, and the Destruction of Communicative Sovereignty". In Davis (ed) 2023, pp. 63–76. Davis, Stuart; Ness, Immanuel. "1: Introduction: Why Are Economic Sanctions a Form of War?". In Davis (ed) 2023, pp. 1–26. Karuka, Manu. "3: Hunger Politics: Sanctions as Siege Warfare". In Davis (ed) 2023, pp. 51–62. Ness, Immanuel. "6: Transnational Allies of Sanctions: NGO Human Rights Organizations' Role in Reinforcing Economic Oppression". In Davis (ed) 2023, pp. 91–104. Wilpert, Gregory. "16: The US War on Venezuela". In Davis (ed) 2023, pp. 273–289. Yaffe, Helen. "8: US Sanctions Cuba 'to Bring About Hunger, Desperation and the Overthrow of the Government'". In Davis (ed) 2023, pp. 129–147. Garlick, Jeremy (2024). Advantage China: Agent of Change in an Era of Global Disruption. Bloomsbury Academic. ISBN 978-1-350-25231-8.
Sources: en.wikipedia.org
=== Table II === acetone anthranilic acid diethyl ether hydrochloric acid (hydrogen chloride) methyl ethyl ketone piperidine sulphuric acid toluene The salts of the substances listed in this Table whenever the existence of such salts is possible. The salts of hydrochloric acid and sulphuric acid are specifically excluded from Table II.
== History == In 1799, British chemist Charles Hatchett experimented with decalcifying the shells of various crustaceans, finding that a soft, yellow and cartilage-like substance was left behind that is now known to be chitin. In 1859, French physiologist Charles Marie Benjamin Rouget found that boiling chitin in potassium hydroxide solution could deacetylate it to produce a substance that was soluble in dilute organic acids, that he called chitine modifiée. In 1894, German chemist Felix Hoppe-Seyler named the substance chitosan. From 1894 to 1930 there was a period of debate and confusion over the exact composition of chitin and particularly whether animal and fungal forms were the same chemicals. In 1930 the first chitosan films and fibres were patented but competition from petroleum-derived polymers limited their uptake. It was not until the 1970s that there was renewed interest in the compound, spurred partly by laws that prevented the dumping of untreated shellfish waste.
Recent studies aimed at measuring and valuing the hidden costs of agrifood systems have used True Cost Accounting (TCA), an accounting approach that measures and values the hidden impacts of economic activities on the environment, society and health. These impacts are regarded as hidden because they are not reflected in the market prices of products and services, i.e. not included in the operational profit and loss accounts.
The 52nd G7 Summit was an annual summit of the G7 held from 15 to 17 June 2026 in Évian-les-Bains, Haute-Savoie, France. Évian-les-Bains previously hosted the 29th G8 summit in 2003. The 2026 summit therefore makes Évian the first French town to host a G7 or G8 leaders' summit twice. At the summit, leaders issued joint statements on Ukraine, the Middle East, critical minerals and global economic imbalances, among other issues.
Sources: en.wikipedia.org
Pilots with gas utilities and biogas plants are underway with companies like Modern Hydrogen. Volume production is also being evaluated in the BASF "methane pyrolysis at scale" pilot plant, the chemical engineering team at University of California - Santa Barbara and in such research laboratories as Karlsruhe Liquid-metal Laboratory (KALLA). Power for process heat consumed is only one-seventh of the power consumed in the water electrolysis method for producing hydrogen. The Australian company Hazer Group was founded in 2010 to commercialise technology originally developed at the University of Western Australia. The company was listed on the ASX in December 2015. It is completing a commercial demonstration project to produce renewable hydrogen and graphite from wastewater and iron ore as a process catalyst use technology created by the University of Western Australia (UWA). The Commercial Demonstration Plant project is an Australian first, and expected to produce around 100 tonnes of fuel-grade hydrogen and 380 tonnes of graphite each year starting in 2023. It was scheduled to commence in 2022. "10 December 2021: Hazer Group (ASX: HZR) regret to advise that there has been a delay to the completion of the fabrication of the reactor for the Hazer Commercial Demonstration Project (CDP).
As of March 2015, Haryana has 11 Centres of Excellent in Horticulture, 3 under construction, 3 newly announced, including the following. This leaves only Punchkula, Panipat, Faridabad, Rewari, Dadri, Jind, and Kaithal districts without any Horticulture CoE or State-level Horticulture Markets.
=== Food safety === Faced with the problem of how and what to feed an astronaut in a sealed capsule under weightless conditions while planning for human spaceflight, NASA enlisted the aid of The Pillsbury Company to address two principal concerns: eliminating crumbs of food that might contaminate the spacecraft's atmosphere and sensitive instruments, and assuring absolute absence of disease-producing bacteria and toxins. Pillsbury developed the Hazard Analysis and Critical Control Points (HACCP) concept to address NASA's second concern. HACCP is designed to prevent food safety problems rather than to catch them after they have occurred. The U.S. Food and Drug Administration has applied HACCP guidelines for the handling of seafood, juice, and dairy products.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.